Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abaloparatide for fracture prevention in postmenopausal osteoporosis
NCT01343004Phase 3Completed
- Sponsor
- Radius Health Inc
- Start
- Apr 2011
- Primary completion
- Oct 2014
- Modality
- Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of abaloparatide in postmenopausal osteoporosis (3 arms), sponsored by Radius Health Inc. Primary endpoint: Number of Participants With New Vertebral Fractures at 18 months. Started Apr 2011; status: completed.
02
Drugs
abaloparatide
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT01343004.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01343004.